Prostate Cancer

Despite the clearly established overall health benefits of exercise, its role in reducing prostate cancer risk is unclear. Whereas some studies found often dramatic reductions in prostate cancer risk, others found no effect.

Perineural invasion was a significant predictor of increased risk for bone metastases in men with prostate cancer who had suspicion for bone metastases after a whole-body bone scan.

Adding chemotherapy to hormonal therapy in men with metastatic hormone-sensitive prostate cancer increased improved overall survival by 13.6 months.

Researchers have identified a subset of six biomarkers that together may predict the risk of more aggressive prostate cancer among African American men.

This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles-both in prostate cancer and for management of other diseases.

Elucidation of the underlying mechanisms of action for Ra-223 will soon expand its clinical utility with respect to improved patient selection and integrated bone-targeted therapies.

The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.

In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.

In this interview, Dr. Mario Eisenberger talks about potential new combination therapies for advanced prostate cancer that are currently being tested in clinical trials.

The management of patients with localized prostate cancer has improved to meet clinical guidelines, according to a new study.

For the first time, researchers say they have been able to use a prostate fusion biopsy to determine which tumors are the most aggressive.

PSA-based screening for prostate cancer among men older than 50 has decreased since the 2012 USPSTF recommendations.

Thanks to the efforts of the Prostate Cancer Foundation and Movember, men of good will (especially those inclined to grow mustaches and raise awareness and funds each year) and their physicians are newly energized to make progress.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

A study showed that prostate cancer patients with bone metastases could have a long-term response to ADT and an acceptable quality of life for 10 or more years.

A small study found that the detection of AR-V7 in advanced prostate cancer patients is not associated with resistance to initial chemotherapy.

Men with prostate cancer assigned to intermittent ADT experienced more ischemic and thrombotic events than did men assigned to continuous ADT.

In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.

Assigning prostate cancer patients in relapse after prostatectomy to ADT and radiation therapy delayed disease progression compared to radiation therapy alone.

Researchers have identified a new histologic subset of metastatic castration-resistant prostate cancer that is refractory to androgen receptor inhibition.

Immediate ADT improved overall survival compared with delayed ADT in prostate cancer patients with a rising prostate-specific antigen level.

The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.

Ahead of the 2015 ASCO Annual Meeting, we are discussing the role of immunotherapy in genitourinary cancers with Susan F. Slovin, MD, PhD.

A large majority of prostate tumors sequenced as part of a comprehensive precision medicine study have mutations that can be targeted with available therapies.